News

Weekly Policy Update: Medical Device Tax and Colorado State Budget

Friday, August 03, 2018

  

Weekly Policy Update: House Repeals Medical Device Tax

Friday, July 27, 2018


On behalf of Colorado BioScience Association thank you for your efforts to secure a yes vote on H.R. 184 - Protect Medical Innovation Act of 2017. We appreciate the time you took to advocate to your representative on the importance of a permanent repeal of the medical device tax credit. In part due to your efforts, this week the U.S. House of Representatives passed H.R. 184, the standalone legislation which permanently repeals the medical device excise tax.  

Weekly Policy Update: Full Repeal of the Medical Device Tax Advocacy

Friday, July 20, 2018

This has been another week with persistent advocacy for full repeal of the Medical device tax in standalone legislation. A permanent repeal of the medical device excise tax remains a top priority for CBSA and Colorado's medtech innovators. While we are appreciative of temporary relief through the two- year suspension as part of the Continuing Resolution to fund the federal government, that abatement is set to expire on December 31, 2019.  

Colorado BioScience Association Announces Departure of President & CEO, April Giles

Monday, July 16, 2018

Board of Directors to Begin National Search for Replacement 
Continue Reading

Weekly Policy Update: Medical Device Tax Advocacy and the CACI Legislative Candidate Interviews

Friday, July 13, 2018

CBSA continues to advocate for a full repeal of the Medical device tax in standalone legislation. A permanent repeal of the tax remains a top priority for CBSA and Colorado's medtech innovators. While we are appreciative for temporary relief through the two-suspension as part of the Continuing Resolution to fund the federal government, the suspension is set to expire on December 31, 2019. 
 

Weekly Policy Update: Meeting with Congresswoman Degette

Friday, July 06, 2018

This week Colorado BioScience Association along with AdvaMed, our Board Chair Scott Larson at Terumo BCT, Zimmer Biomet and ResMed met with Congresswoman DeGette. The meeting offered a great opportunity to talk about the importance of our industry and the exciting innovations taking place, as well as barriers presenting current challenges.  

Weekly Policy Update: Primary Elections, Congratulating Sen. Gardner, and Drug Pricing

Thursday, June 28, 2018

2018 COLORADO PRIMARY ELECTION
 
Continue Reading

Sapphire Technology Completes a Nationwide Distribution Agreement With Burkhart Dental Supply

Wednesday, June 27, 2018

Denver-based dental instrument company, Sapphire Technology, recently completed a nationwide distribution agreement with Burkhart Dental Supply (Tacoma, WA). Burkhart will soon market and sell Sapphire’s innovative and proprietary line of SGS® sapphire-tipped composite dental instruments. Established in 1888, Burkhart is one of the oldest and most established distributors of dental products. The SGS® instruments are intended to work correctly and ideally with dental restorations employing composite resin restoration materials – now the most prevalent dental restoration material. In addition to acquiring Burkhart as a distributor, Sapphire received a European Patent for its dental instruments. Sapphire was also issued a 2nd US patent.  

New Office Location Helps Packaging Compliance Labs Accelerate Growth In Healthcare Packaging

Monday, June 25, 2018

Packaging Compliance Labs, a top medical device and pharmaceutical packaging engineering and validation firm, recently opened a new office in the heart of downtown Denver, Colorado, to accommodate rapid growth and leverage the area’s growing biotechnology industry.  

Weekly Policy Update: FDA Releases Important Guidances

Thursday, June 21, 2018

The FDA recently announced the release of important guidances, “Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities–Questions and Answers,” and “Medical Product Communications That Are Consistent With the FDA-Required Labeling”. The first guidance answers common questions about companies’ communications to payors, including insurance companies, formulary committees and similar entities. The second guidance provides the FDA’s views on manufacturers’ communication of information that is not contained in the FDA-required labeling for their products, but that is consistent with that labeling. Both guidances are critical to outline how companies can communicate off-label health care economic information about their products to health plans, hospitals and other drug purchasers.